United Therapeutics Corporation (UTHR) NASDAQ

Currency In USD

AD

United Therapeutics Corporation

Address

1040 Spring Street

Silver Spring, MD 20910

United States of America (the)

Phone

301 608 9292

Sector

Healthcare

Industry

Biotechnology

Employees

1400

First IPO Date

June 17, 1999

Key Executives

NameTitlePayYear Born
Martine A. RothblattFounder, Chairman & Chief Executive Officer5.84M1955
Paul A. MahonExecutive Vice President, General Counsel & Corporate Secretary2.49M1964
James C. EdgemondChief Financial Officer & Treasurer2.59M1968
Michael I. BenkowitzPresident & Chief Operating Officer4.81M1972
Leigh PetersonExecutive Vice President of Product Development & Xenotransplantation0N/A
Harrison SilversManager of Investor Relations0N/A
Gil GoldenSenior Vice President & Chief Medical Officer0N/A
Patrick PoissonExecutive Vice President of Strategic Development01968
Holly HobsonAssociate Vice President of Human Resources0N/A
AD

Description

United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.

AD